| Literature DB >> 35600945 |
Lu Wang1, Mingwei Yu1, Yunfei Ma1, Rong Tian2, Xiaomin Wang1.
Abstract
Pulmonary rehabilitation (PR) has a curative effect in patients undergoing pneumonectomy for lung cancer. Nevertheless, the contribution of PR to the clinical status of patients with chronic obstructive pulmonary disease (COPD) undergoing lung resection has not been adequately elucidated. The aim of this systematic review of randomized and nonrandomized controlled trials was to appraise the impact of PR compared to conventional treatment based on postoperative clinical status in patients with lung cancer and COPD. Literature in English from PubMed, Cochrane Library, Science Citation Index, and Embase databases and in Chinese from the Chinese National Knowledge Infrastructure and the WANFANG Database was retrieved from inception to November 2021, employing the keywords "Pulmonary Neoplasms," "Chronic Obstructive Pulmonary Diseases," "Physical Therapy Modalities," and "pulmonary rehabilitation." Only studies that reported PR results were included. This review was registered in the International Prospective Register of Systematic Reviews (number: CRD42021224343). A total of nine controlled trials with 651 patients were included. Postoperative pulmonary complications (PPCs) were the primary outcome measure. PR decreased the risk of complications after surgery compared to regular treatment (odds ratio (OR) 0.21, 95% confidence interval (CI) 0.12-0.37, P < 0.01). PR reduced the risk of pneumonia after surgery compared to regular treatment (OR 0.36, 95% CI 0.15-0.86, P=0.02). There was a significant difference in the postoperative length of stay (mean difference -2.13 days, 95% CI -2.65 to -1.61 days, P < 0.05). PR was an effective intervention that decreased PPCs in patients suffering from lung cancer and COPD. However, due to the limitations of the available data, the results should be interpreted with caution.Entities:
Year: 2022 PMID: 35600945 PMCID: PMC9122671 DOI: 10.1155/2022/4133237
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
Figure 1Flow diagram of study selection.
Characteristics of included studies.
| Study (country) | Year | Study design | Total participants, | Intervention group (I), | Characteristics | Comparison | Outcome measurements |
|---|---|---|---|---|---|---|---|
| Stefanelli et al. [ | 2013 | RCT | 40 (23/17) | I: 20 (<75) | NSCLC (stage I/II) and COPD; open thoracotomy | Usual care (preoperative preparation) | CPET |
| Zhang and Zhao [ | 2011 | RCT | 19 (9/10) | I: 10 (70.2 ± 8.61) | Lung cancer and COPD; open thoracotomy or VATS | Usual care (preoperative preparation) | PPCs |
| Zhang et al. [ | 2014 | RCT | 86 (56/30) | I: 43 (64.98 ± 2.7) | NSCLC (stages I–III) and COPD; open thoracotomy or VATS | Usual care (preoperative preparation) | PPCs |
| Lai et al. [ | 2016 | RCT | 48 (28/20) | I: 24 (63.13 ± 6.26) | NSCLC (stages I–IV) and COPD; open thoracotomy or VATS | Usual care (preoperative preparation) | PPCs |
| He [ | 2018 | RCT | 110 (72/38) | I: 55 (68.5 ± 5.6) | NSCLC and COPD; open thoracotomy or VATS | Usual care (preoperative preparation) | PPCs |
| Saito et al. [ | 2017 | CT | 62 (54/8) | I: 31 (72.0 ± 8.8) | NSCLC (stages I–II) and COPD; open thoracotomy or VATS | Usual care (preoperative preparation) | PPCs |
| Mujovic et al. [ | 2015 | CT | 103 (90/13) | I: 56 (72.0 ± 8.8) | NSCLC and COPD; open thoracotomy or VATS | Usual care (preoperative preparation) | LOS |
| Sekine et al. [ | 2005 | CT | 82 (76/6) | I: 22 (70.4 ± 4.6) | NSCLC (stages I–IV) and COPD; | Usual care (preoperative preparation) | PPCs |
| Meng et al. [ | 2018 | CT | 101 (63/38) | I: 43 (58.9 ± 8.9) | NSCLC (stages I–III) and COPD; VATS | Usual care (preoperative preparation) | PPCs |
RCT: randomized controlled trial; I: intervention group; C: control group; COPD: chronic obstructive pulmonary disease; SD: standard deviation; LOS: length of stay; NSCLC: non-small-cell lung cancer; PFT: pulmonary function testing; PPC: postoperative pulmonary complication; CPET: cardiopulmonary exercise test; 6MWD: 6-minute walking distance; VATS: video-assisted thoracoscopic surgery; CT: controlled trial.
Summary of interventions.
| Studies | Length of intervention | Duration of sessions | Type | Intensity | Frequency |
|---|---|---|---|---|---|
| Stefanelli et al. [ | 3 weeks | 3 hours | Lower limbs by treadmill and ergometric bicycle, respiratory exercises, and upper limbs with rowing ergometer | Started with 70% of the maximum score reached at the cardiopulmonary exercise test and increased by 10W when the patient was able to tolerate the set load for 30 min | 5 per week |
| Benzo et al. [ | 1 week | 15–20 minutes | Inspiratory muscle training, lower extremity endurance training, respiratory exercises, and strengthening exercises | If the patient perception was “too easy” or “requires no effort,” resistance was increased | Daily |
| Zhang and Zhao [ | 2 weeks | 35–50 minutes | Intense training (respiratory training and endurance training) | The exercise intensity was controlled within the target heart rate range | Daily |
| Lai et al. [ | 1 week | 15–30 minutes | Intense training (respiratory training and endurance training) | The amount of exercise was adjusted between Borg 5 and 7 | Daily |
| He [ | 2 weeks | 15 minutes | Intense training (respiratory training and endurance training) | The amount of exercise was adjusted between Borg 5 and 7 | Daily |
| Saito et al. [ | 4 weeks | Peripheral muscle exercise training and respiratory exercise, postoperative PR | Not mentioned | 5 per week | |
| Mujovic et al. [ | 2–4 weeks | 45 minutes | Intense training (respiratory training and endurance training) | Not mentioned | 5 per week |
| Sekine et al. [ | 2 weeks | 30 minutes | Abdominal breathing and breathing exercises and walking more than 5,000 steps | Not mentioned | Daily |
| Meng et al. [ | 7–10 days | 20–30 minutes | Intense training (respiratory training and endurance training) | Not mentioned | Daily |
Figure 2Forest plots comparing intervention and control groups in patients with lung cancer and chronic obstructive pulmonary disease (COPD) who were surgically treated. (a) Risk of postoperative pulmonary complications in randomized controlled trial (RCT). (b) Incidence of postoperative pneumonia in RCT. (c) Risk of postoperative pulmonary complications in computed tomography (CT) studies. (d) Incidence of postoperative pneumonia in CT studies.
Figure 3Forest plots of effect estimates of pulmonary rehabilitation (PR) versus controls on FEV1 (L).
Figure 4Forest plots of effect estimates of pulmonary rehabilitation (PR) versus controls on postoperative length of stay (LOS). (a) RCT studies that reported postoperative LOS. (b) CT studies that reported postoperative LOS.